Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JPMA Petition Calls For Increases in PMDA Reviewers
July 31, 2006
- SEMINAR
July 31, 2006
- Anact C's Approval Recommended for Purpura Fulminans
July 31, 2006
- Japanese Breast Cancer Society Drug Treatment Guidelines Amended
July 31, 2006
- COMMENTARY an article
July 31, 2006
- Arteriosclerosis Treatment GL under Amendment
July 31, 2006
- 1st Committee Recommends 3 New Drugs for Approval
July 31, 2006
- Leukemia Treatment Advances with Approval of Glivec
July 31, 2006
- Korosho to Again Cut \220 Billion in Natural Hike in Social Security Spending in FY2007
July 31, 2006
- 14th Clinical Pharmacy Symposium
July 31, 2006
- SEMIANR
July 31, 2006
- NEW PRODUCTS
July 31, 2006
- BUSINESS NEWS IN BRIEF
July 31, 2006
- Ranbaxy Acquires GSK's Generic Drug Business in Spain
July 31, 2006
- Wholesalers Have Not Yet Even Offered New Prices: NPhA
July 31, 2006
- Japanese Version of Critical Path Opportunity Report Published by JPMA
July 31, 2006
- Asahi Kasei Sees Healthcare as Core "High Growth Business"
July 31, 2006
- R&D NEWS IN BRIEF
July 31, 2006
- Original Clarithromycin Tastes Better than Generics: Taisho Toyama
July 31, 2006
- Drug Development Beyond Borders -Today's Global Cooperative Clinical Trials- Part III: Pfizer's Views
July 31, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…